112968-89-5

Basic information

• Product Name: Benzene, 1-bromo-4-[2-(2-methoxyethoxy)ethoxy]-
• CAS NO: 112968-89-5
• Molecular Formula: C11H15BrO3
• Molecular Weight: 275.142
• Mol File: 112968-89-5.mol
• Article Data: 8

Chemical Properties

• CAS DataBase Reference: Benzene, 1-bromo-4-[2-(2-methoxyethoxy)ethoxy]-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzene, 1-bromo-4-[2-(2-methoxyethoxy)ethoxy]-(112968-89-5)
• EPA Substance Registry System: Benzene, 1-bromo-4-[2-(2-methoxyethoxy)ethoxy]-(112968-89-5)

Safety Data

• Hazardous Substances Data: 112968-89-5(Hazardous Substances Data)

Upstream product

• 106-41-2 4-bromo-phenol 
• 54149-17-6 2-bromoethyl 2-methoxyethyl ether 
• 111-77-3 2-(2-methoxyethoxy)ethyl alcohol 
• 80392-30-9 diethylene glycol methyl phenyl ether 
• 50586-80-6 toluene-4-sulfonic acid 2-(2-methoxyethoxy)ethyl ester 

Downstream Products

• 1366602-62-1 2-(4-(2-(2-methoxyethoxy)ethoxy)phenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane 
• 112968-90-8 1-(4-allylphenoxy)-5-methoxy-3-oxapentane 

Relevant articles and documents

A double branched photosensitive prodrug: Synthesis and characterization of light triggered drug release

A novel oNB based, double branched photosensitive prodrug 1, and a biphenyl counterpart 2 were designed and synthesized. Their photo-triggered drug release properties were studied by HPLC and UV-vis spectra. The isobestic points in UV-vis spectra of prodr

Quantitative real time sensing reveals enhanced sensitivity of polar dendrimer thin films for plastic explosive taggants

A method of introducing pulses of analyte vapours has been developed to study the interactions of nitro-containing analytes with fluorescent sensing films. The quenching of the photoluminescence of thin dendrimer films by exposure to sub-saturation concen

MORPHINAN DERIVATIVES FOR THE TREATMENT OF NEUROPATHIC PAIN

The present invention relates to compounds and their use as ligands for mu opioid receptors. Also included are methods for preparing the compounds and pharmaceutical compositions containing the compounds. In one or more embodiments of the invention, a compound according to Formula I is provided: and pharmaceutically acceptable salts thereof, wherein R1-R11 are as described herein.